- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
AGI chief joins XP advisory board
Freeport, N.Y. - Daniel B. Yarosh, Ph.D., president and CEOof AGI Dermatics, has been named to the Xeroderma PigmentosumSociety's Scientific Advisory Board.
Freeport, N.Y. - Daniel B. Yarosh, Ph.D., president and CEO of AGI Dermatics, has been named to the Xeroderma Pigmentosum Society's Scientific Advisory Board.
An acclaimed molecular biologist who has devoted 20 years to studying the effects of sun on DNA and skin, Dr. Yarosh is the inventor of Dimericine. This first therapeutic DNA repair enzyme can reduce the incidence of pre-cancers and basal cell carcinoma. Dimericine is currently in clinical testing for Food and Drug Administration approval as a topical prescription drug.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
